ABSTRACT
INTRODUCTION
Minimally invasive surgery for gynecological procedures has gained worldwide acceptance. This specialty is forever optimistically moving forward in hope of performing safe surgical procedures with cosmetically smaller and fewer scars to the patient, as well as improving peri/postoperative surgical outcomes. With the progression in the learning curve, surgeons are now inclined to perform more challenging procedures, such as myomectomy via the minimally invasive route.
Clinical advantages of conventional multiport laparoscopic myomectomy over abdominal myomectomy in young women seeking fertility preservation are now well proven. [1] [2] [3] Furthering the minimally invasive approach, laparoendoscopic single-site surgery (LESS) has been adopted by the surgeons due to better cosmetic acceptance by the patients. 4, 5 Additionally, the wider umbilical access associated with LESS provides for an alternative to electromechanical morcellator for contained mechanical tissue extraction. This feature becomes more relevant to gynecologic surgeons owing to the recently imposed ban by US Food and Drug Administration (FDA) on the use of electromechanical morcellators. 6 However, the use of LESS for myomectomy has not gained wide popularity due to intensive reconstruction and suturing required as well as lack of proven robust surgical benefits when compared with conventional multiport myomectomy. [7] [8] [9] Other challenges posed by LESS like manipulation of three articulating instruments through one access port, lack of triangulation, instrument crowding or clashing, poor ergonomics, and a long learning curve make it a less favored choice for a demanding surgery, such as myomectomy.
The commercial availability of robotic da Vinci surgical system (Intuitive Surgical inc., Sunnyvale, California, USA) has attracted the gynecologic surgeon's interest due to proposed favorable surgical ergonomics, greater precision in dissection, and easier suturing as well as knot tying. Robot-assisted laparoscopic myomectomy has shown similar surgical outcomes as conventional laparoscopy and has gained acceptance as a safe and reproducible operation. [10] [11] [12] [13] Robot-assisted laparoendoscopic single-site surgery appears to be encouraging for more suture intensive surgeries like myomectomy as it offers potential in resolving the ergonomic challenges imposed by the restrictive range of motion and vision of conventional LESS. 14 The aim of this review is to appraise the available literature on RA-LESS myomectomy and comment on the feasibility, reproducibility, and learning curve as well as financial implication of this technique.
MATERIALS AND METHODS
An electronic search was conducted using relevant keywords and Mesh terms like single port, single incision, single site, laparoscopic myomectomy, robotic assisted. PubMed, Google Scholar, and Cochrane central register for controlled trials databases were searched to identify pertinent studies from 2010 to 2017. Studies where hybrid techniques, that is, robotic assistance combined with any other technique like conventional single site/multiport, mini laparotomy were not included. As RA-LESS is a relatively newer technique, it was decided to include case studies, case series, retrospective as well as prospective cohort studies for analysis. Statistical Package for the Social Sciences software was used for statistical analysis where required. 15 were the first to publish their experience with robotic single-site myomectomy using the da Vinci Si Surgical System in four patients. This was followed by a step-by-step tutorial of their technique and results from their first series of 10 women. 16 Consecutively, in 2017, two studies were published; one was a retrospective analysis of 61 cases by Choi et al 17 and another a prospective cohort of 21 patients by Gargiulo et al. 18 Comparison of the outcomes is listed in Table 1 .
RESULTS
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Most of the patients in all the studies had a high body mass index (BMI). The mean size of the largest myoma that was enucleated was 6.73 ± 2.04 cm by Choi et al 17 and 5.7 ± 1.9 by Gargiulo et al 18 and the largest myoma stood at 12.8 cm in diameter. Maximum number of myomas removed from a single patient was 12. All types including intramural, submucosal (International Federation of Gynecology and Obstetrics 2), subserosal, broad ligament, and retroperitoneal as well as anterior, is feasible and can be safely offered in women with higher BMI without apprehension of conversion. Also, the deep umbilicus in obese women also provides the benefit of cosmetically more acceptable surgical scar. The RA-LESS technique is usually associated with a larger incision when compared with the conventional multiport laparoscopic surgery. One of the studies reported the mean skin incision as 2.70 ± 0.19 (2.4-3.10) cm. 17 With the controversy over the use of electromechanical morcellator and its recent ban by the US FDA, RA-LESS provides a unique opportunity to mechanically retrieve the myoma specimen using knife with the same incision, which, in turn, saves operative time. This seems to be a benefit over the robotic/laparoscopic multiport myomectomy where an additional minilaparotomy/or extension of the incision will be needed to extract the tissue if the use of electromechanical morcellator has to be avoided. All the studies [15] [16] [17] [18] in this review combined their technique of RA-LESS with contained endobag mechanical morcellation for tissue retrieval suggesting that this technique can be easily adapted by gynecologic surgeons in the absence of availability of morcellators. Surgical access to multiple myomas might be a point of concern while considering LESS owing to the technical challenges associated with conventional LESS technique. All the studies, however, suggested that myomas of all types including intramural, subserosal, and submucosal as well as all location anterior, posterior, fundal, broad ligament, and retroperitoneal are amenable to dissection. Choi et al 17 However, the present data are limited to comment on the exact indications or contraindications for this procedure, and patient selection criteria in terms of type, location, or size of myoma will evolve with the growing experience.
The operating time of LESS surgery is usually longer than that of the conventional multiport laparoscopic surgery. 24 patients into three groups based on the largest myoma diameter (< 6, 6-10, and >10 cm). The mean myoma diameter was 4.99 ± 0.79 cm in the < 6 cm group, 7.33 ± 0.90 cm in the 6 to 10 cm group, and 11.66 ± 0.99 cm in the >10 cm group. There were no statistically significant differences across the three groups in total operation time. However, the expected blood loss was lowest in the <6 cm group (132.80 ± 122.32 mL) compared with the other two groups (210.97 ± 157.72 mL in the 6 to 10 cm group and 256.00 ± 215.48 mL in the >10 cm group), representing a statistically significant trend (p = 0.078).
It is important to note that robotic myomectomy is a significantly lengthier procedure compared with conventional laparoscopic myomectomy, 13 but the robotic platform allows for a broader range of applications compared with conventional laparoscopy for this indication. Also, the obese can realize the same clinical and quality benefits of minimally invasive surgery as the nonobese at the cost of additional operative time.
One of the aims of this study was to analyze the comprehensive cost of this procedure. However, none of the studies reported on the cost analysis. Only one study compared the robotic modality with its laparoscopic counterpart and found an associated higher cost with the robotic technique. 18 This is an important area that needs to be further studied, especially, to understand if a wider application of this technique is economically feasible. Another limitation is that in all the studies, the surgeries were performed by highly experienced surgeons in the field of minimally invasive and robot-assisted surgery, and it is, therefore, unclear whether these techniques would translate to successful adoption by the larger surgical community.
CONCLUSION
Current initial data indicate that RA-LESS is a promising technique. It is a safe, feasible, and reproducible procedure for performing myomectomy. However, more studies with larger cohorts and long-term follow-ups are needed to conclusively recommend this technique for a wider application. Also, the exact indications for its use and patient selection criteria for optimum outcome still need to be determined.
